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Based on its PK/PD ratios, doxycycline hyclate (DOX-h), a time-dependant antibacterial, is ideally expected to
achieve both sustained plasma drug concentrations at or slightly above the MIC level for as long as possible
between dosing intervals. Pursuing this end, a poloxamer-based matrix was used to produce a long-acting
injectable preparation (DOX-h-LA) and its serum concentrations vs. time profile investigated after its SC injection to
dogs (≤ 0.3 mL per injection site), and results compared with the oral (PO) and IV pharmacokinetics of DOX-h,
prepared as tablet or as freshly made solution. A crossover (4 x 4 x 4) study design was employed with 12 Mongrel
dogs, with washout periods of 21 days, and at dose of 10 mg/kg in all cases. DOX-h-LA showed the greatest values
for bioavailability (199.48%); maximum serum concentration (Cmax) value was 2.8 ± 0.3 with a time to reach Cmax
(Tmax) of 2.11 ± 0.12 h and an elimination half-life of 133.61 ± 6.32 h. Considering minimum effective serum
concentration of 0.5 μg/mL, a dose-interval of at least 1 week h can be achieved for DOX-h-LA, and only 48 h and
24 h after the IV or PO administration of DOX-h as a solution or as tablets, respectively. A non-painful small bulge,
apparently non-inflammatory could be distinguished at injection sites. These lumps dissipated completely in
30 days in all cases.
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Doxycycline (Dox), a semi-synthetic derivative of oxy-
tetracycline, is an inexpensive, potent antibacterial drug
commonly used as doxycycline hyclate (DOX-h). It dif-
fers from oxytetracycline, chlortetracycline and tetracyc-
line in that it is 5–10 times more lipophilic [1]; hence, it
possesses higher tissue penetration, larger volume of dis-
tribution and better antimicrobial properties, consider-
ing that entry into bacteria is not dependant on an
active transportation mechanism as it occurs with the
above referred tetracyclines. Additionally, Dox has a
more prolonged half-life and a greater plasma protein
binding rate [2], both in humans and animals.
The broad spectrum-antimicrobial effects of DOX-h
are based on hindering bacterial protein synthesis, by
interference with the binding of aminoacyl-tRNA to the
mRNA ribosome complex thus arresting growth [3,4].
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reproduction in any medium, provided the orclinical results when the drug is administered to comply
with a time-dependant action [5,6]. That is, serum con-
centrations of DOX should ideally never be below the
MIC at any time during the dosing interval [7]. In dogs,
DOX has been listed as drug of choice to treat bacterial
infections caused by Haemobartonella canis, Staphylococus
spp, Streptococcus spp, Haemophilus spp, Bordetella
bronchiséptica, Mycoplasma spp Leptospira spp, Erclichia
canis, Borrelia burgdorferi, Brucella canis, Campylobacter
jejuni, Fusobacterium spp. [1,6,8,9]. To treat diseases causes
by these bacteria, DOX is customary administered as
tablets once or twice daily in prolongued dosing schemes.
However, compliance with long-term dosing is often de-
fective, either by negligence or caused by vomiting and
other gastrointestinal adverse drug reactions [2]. Injection
of an aqueous preparation of DOX-hyclate is not an op-
tion because as it occurs with other tetracyclines, this drug
is remarkably tissue-irritating [1,8,10], a fact that also
explains the lack of an injectable long-acting (LA) prepar-
ation. A possible exception can be found in the poloxamer
β-cyclodextrin-based matrix, long acting formulation of
doxyclyne (DOX-h-LA) that has been proposed for cowsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cokinetics and a minimum irritation at the injection site
were found.
Considering the above, the objectives of this study
were: establish the pharmacokinetics of the referred ex-
perimental preparation of DOX-h-LA after its SC injec-
tion at a dose of 10 mg/kg of body weight in volumes of
injection not greater than 0.3 mL, and to compare these
results with the pharmacokinetics of DOX-h after the
oral administration of tablets or the IV injection of a
freshly made aqueous solution.
Material and methods
This study was approved by the Institutional Committee
of Research, Care and Use of Experimental Animals
(CICUAE), according to de Mexican Official Regulation
NOM-062-ZOO-1999. This study was carried out at the
Facultad de Medicina Veterinaria y Zootecnia at the Uni-
versidad Nacional Autonoma de Mexico, located in
Mexico City.
Twelve clinically healthy mongrel dogs 2–9 years old
(7 males and 5 bitches), weighing 18±4.2 kg (range:
10–23 kg), were included in this trial. Upon arrival to the
Veterinary College, animals were dewormed with an
oral ivermectin-praziquantel preparation (Pet-GardW,
from Cpmax Pharmaceuticals, Mexico). Dogs were fed
ad libitum with commercial pelleted feed (Pro-PlanW,
Purina México), and allowed to get accustomed for
15 days to new surroundings in individual-ground 2 x
3 m cages, with free access to clean drinking water
and 1 h daily walks. No antibacterial or any other
medication was administered for at least 15 days prior
to receiving their injection or tablet of DOX-h. To as-
sign dogs to a given treatment a three way crossover
model (4 x 4 x 4) was used, with a washout period of
21-days. For all animals, a foster family was ensured
after the study.
A subcutaneous LA preparation (100 mg/mL) of doxy-
cycline hyclate was developed (PARFARM Pharmaceuticals,
Mexico City, Mexico), under sterile conditions. Inclusion
complexes of doxycycline 10% (w/v) with β-cyclodextrin
(1:0.1 M) (Cerestar Pharmaceutical Excipients, U.S.A.) were
first formed by the kneading method which can be
described as follows: β-cyclodextrin (0.1 M) and distilled
water were mixed together in a mortar so as to obtain a
homogeneous paste. Then, doxycycline (1 M) was added
slowly. The mixture was ground for 30 min and an appro-
priate quantity of water was added to maintain a paste-like
consistency. It was then dried in oven at 40-50˚ C for 24
hours. The dried complex was pulverized into a fine pow-
der [13]. The resulting powder was diluted with a solution
of 15% propylenglycol - 10% ethyl alcohol in water. Then,
this mixture was included in a reverse gel copolymer poly-
oxypropile–polyoxyethylene (poloxamer) BASF (MexicoCity, Mexico) adjusting pH to 7.0 with a phosphate buffer
solution under constant stirring at 4° C to reach a final con-
centration of 10% of doxycycline in 15% poloxamer. The
preparation was regarded as ready when a micro-emulsion
is formed and this can be pin-pointed when the mixture
clarifies (Patent No: 289266, Instituto Mexicanos de la Pro-
piedad Industrial; April 25, 2997). Then, 10 ml vials were
prepared, stored at 4 °C and utilized during the following
week.
Ten percent aqueous solutions were made from pow-
der DOX-h diluted in sterile distilled water immediately
before injection. A dose of 10 mg/kg in a volume ap-
proximately 1 mL/10 kg of body weight was adminis-
tered intravenously through the cephalic vein using a
catheter No. 20 (Becton, Dickinson and Company,
México). The experimental, long-acting preparation of
DOX-h developed for this trial (DOX-h-LA), was
injected SC at the same dose of 10 mg/kg, but in equally
divided volumes never exceeding 0.3 mL per site, in the
costal area. Two hundred and fifty mg tablets of doxy-
cycline were administered by concealing them in 200 g
pork-sausages and ensuring their complete consump-
tion. Dose was adjusted to 10 mg/kg by scraping the tab-
let to quadrate to each individual weight. In all three
groups adverse drug reactions were sought for with hour
to hour observations during the day.
Individual dose vs. pharmaceutical preparation compli-
ance was calculated to have 6.5, 4.2 and 3.8% error from
the set dose of 10 mg/kg for tablet, LA and aqueous
preparation, respectively, as assessed by determining
Dox concentration in all three preparations, taking 4
random test samples of each group.
In order to achieve a close timing interval between ad-
ministration of the drug and blood sampling from the
radial vein, a permanent-heparinized 5-inch long cath-
eter gauge No. 20 (Becton, Dickinson and Company,
México City) was placed in each dog and a plastic collar
ensured to avoid dogs from reaching the catheter. Three
mL blood samples were withdrawn after discarding the
first 2 mL of heparinized blood. The times for collection
after administration of the drug were: 0, 0.5, 1, 2, 3, 4, 6,
8, 10, 12, 24, 48, 72, 60, 72, 84, 96, 108, 120, and 200 h.
Blood samples were immediately centrifuged, plasma
recovered, identified, and frozen at -20° C until analyzed
within five days.
Serum doxycycline concentrations were determined by
the modified agar diffusion analysis, described by Abd
El-Aty et al.[14] with Bacillus cereus (ATCC-11778) as a
test organism grown on Müeller-Hinton agar (MCD
LAB, S.A. de C.V., México City). Drug concentrations
were determined by comparing the diameter of zones of
inhibition with those of various dilutions of the standard
prepared in pooled antibacterial-free dog serum by the
use of linear regression analysis. The intra-assay
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<4.8. The analytical assay was linear over a range of
concentrations from 0.05 to 10 μg/mL,with a percent re-
covery of 94 ± 2 and a correlation coefficient (r2) of
0.97 ± 0.1. Limit of detection was 0.005 μg/mL and limit
of quantification was 0.01 μg/mL. A computerized
curve-stripping program (PKAnalystW, Micromath Sci-
entific Software, SLM, USA) was used to fit and analyze
the concentration vs. time profiles of each individual
dog and mean values later derived. Best fitting models
were chosen after analysis with residual sum of squares
and the minimal Akaike’s information criterion. For the
PO route best fit was obtained using a two compartment
models with first–order input and first–order output
using (Model 11, r ≥ 0.99), whose formula is:
Concentration Timeð Þ ¼ Dose  KAB
Volume KAB  Kelim e
kelimTime
eKABTime:
For the SC route best fit was obtained using a two com-
partment models with first–order input and first–order
output using (Model 13, r≥0.99), whose formula is:
Concentration Timeð Þ ¼ Aea Time þ Beb Time
 CeKAB  Time:
The concentration-time curve of DOX-h IV was best
fitted using a two compartment model as presented in
Model 7 (r≥ 0.99), with the following formula:
ConcentrationðTimeÞ ¼ AeαTime þ BeβTime:
Pharmacokinetic variables obtained with PKAnalyst
for the IV route were: AUC0-∞ = Area under the
curve; AUMC0-∞ area under the moment curve; RT =
retention time; A, B, = zero time intercepts of the
distribution and post-distribution phases; α and β =
hybrid rate constants for the distribution and elimin-
ation phases, respectively; T½β = half-life of the elim-
ination; Cs0 =maximum serum concentration at time
zero. Other variables, such as Vdc = Volume of the
central compartment; Vdarea = Volume calculated by
the area method; Vdss = apparent volume of distribu-
tion at steady-state and CLB = clearance from the
body were obtained with standard formulas, as pro-
posed by [15,16].
Pharmacokinetic variables obtained for the extravascu-
lar route were: AUC0-∞ = Area under the concentration-
time curve from zero up to ∞ with extrapolation of the
terminal phase; AUMC=Area under the first moment of
the concentration-time curve; AUCt =Area under the
concentration-time curve calculated by the trapezoidal
method; AUMCt =Area under the first moment of the
concentration-time curve calculated by the trapezoidalmethod; RT=Retention time; K½el = Elimination half
rate constant from the central compartment; K½ab=Ab-
sorption half rate constant from the central compartment;
A, B, = zero time intercepts of the distribution and post-
distribution phases; α and β=hybrid rate constants for the
distribution and elimination phases, respectively; T½β=
half-life of the elimination; Cmax=Calculated maximum
plasma concentration; Tmax=Time of maximum plasma
concentration; F=Bioavailability.
Two bioavailability (F%) values were calculated using
the following equation:






Data are presented as mean± standard deviation of 12
observations for each parameter and for statistical com-
parisons of Cmax, Tmax, AUC, RT and T½β among
groups the Kruskal-Wallis and Dunn-test, were used.
Results
Mean ± 1 SE plasma concentrations vs. time profiles of
DOX-h in dogs after a single bolus IV dose of the aque-
ous preparation of the drug, a single dose of the drug as
a tablet and after the SC administration of the experi-
mental preparation, are presented in Figure 1. Table 1
summarizes all pharmacokinetic variables obtained,
which showed no normal distribution for the three
groups. A statistical comparison, made for those vari-
ables shared by the three administration routes, is also
presented in Table 1.
Comparisons for AUC, RT and T½β, showed that all
these variables were statistically larger in group DOX-h-LA
as compared to groups DOX-h-IV or DOX-h-PO (P ran-
ging from <0.05 to <0.001). Bioavailability values for
the DOX-h-LA group were 199.48%, while the same
variable for the DOX-h-PO group was 74.88%. The half
rate constant from the central compartment obtained
were 45.21 ± 0.74 h for DOX-h-LA 5.59 ± 0.03 h for the
DOX-h-PO, and 2.87 ± 0.02 h for DOX-h-IV. Differ-
ence among these statistical means half rate constant
from the central compartment obtained for Dox-h-LA
was statistically longer (P< 0.001).
Based on an arbitrary minimal therapeutic concentra-
tion a comparative assessment was made of the length
of time for which a given serum concentration of dox-
yxycline was maintained. Chosen value was 0.12 μg/mL
[1,17,18]. Under this setting, DOX-h-IV maintained suit-
able serum concentrations for 8 h; DOX-h-PO for 22 h
and DOX-h-LA extended these time-periods to approxi-
mately 200 h. The time at which serum concentrations
of Dox were at an appropriate level were statistically dif-
ferent when comparing DOX-h-LA with either DOX-
h-IV and DOX-h-PO (P< 0.001).



















Figure 1 Mean ± 1 SD plasma concentrations (Log10) vs. time profiles of doxycycline in dogs after a single bolus IV dose of an
aqueous preparation of the drug, a single dose of the drug as a tablet and a single SC injection of an experimental long-acting
preparation. Dose was 10 mg/kg in all cases.
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yet, no typical inflammatory response was observed at the
injection site with the DOX-h-LA preparation. However, a
well defined apparently painless bulge remained detectable
for up to 30 days. These lumps began with an approximate
diameter size of 1.5 - 2 cm and disappeared steadily. These
bulges are not believed to be inflammatory responses, but
rather space occupied lumps caused by the poloxamer
when becoming gel at body temperature. After 30 days no
lesion could be detected. Animals did not show any un-
usual sign of pain or discomfort with the long-acting prep-
aration either when injected or afterwards.
Discussion
The quantitative/qualitative microbiological agar diffusion
technique used in this trial to determine serum concentra-
tions of doxycycline has been regarded as sufficiently reli-
able to replace analytical conclusions derived from high
performance liquid chromatography [19]. Furthermore,
because it determines the active fraction(s) of the drug, it
offers more clinically meaningful data than concentration
values derived from purely chemical methods. In turn, this
allows straight forward speculations on the relationships
between serum concentrations, clinical efficacy and dosing
intervals for specific pathogens.
The pharmacokinetics of DOX-h has been reported
in dogs following its IV administration [20]. Variables
described by these authors and reported values in this
study are very much in agreement. For example Cp0
with a 10 mg/kg dose was 23.54 ± 4.32 in this trial,and 11.77 ± 2.26 μg/mL in the referred study with a
dose of 5 mg/kg; AUC was 109.66 ± 8.56 μg.h/mL and
52.76 ± 15.34 μg.h/mL for obtained and reported
results, respectively and elimination half-life was
0.09 h in both cases. The half-life value obtained for
DOX-h-IV in this study falls within the range docu-
mented for other species varying from 4.2 h to 16.6 h
[10,21-24]. However, no studies are available on the
pharmacokinetics of neither the oral administration of
the drug as tablets, nor the SC injection of a long-
acting preparation, in dogs.
The preparation DOX-h-PO resulted in Cmax values
twice that of the DOX-h-LA group (5.58 ± 0.5 μg/mL vs.
2.8 ± 0.3 μg/mL), and Tmax occurred in 3.9 ± 0.4 and
2.11 ± 0.1 h, respectively. After Cmax, serum concentra-
tions of DOX declined slowly with a K½el of 45.21 h in
the DOX-h-LA group, which is a value considerably lar-
ger than the corresponding one in PO group (K½el of
5.59 h). Predictably for a highly lipid soluble drug, a high
apparent volume of distribution area was achieved after
IV administration of the drug (Vdarea = 1.49 ± 0.27 L/kg.
Retention time (RT) was considerably larger in the
DOX-h-LA group (166.63 ±5.58 h) vs. 10.10 ± 1.12 h and
10.22 ± 2.21 h for the IV and PO groups, respectively.
Absolute bioavailability of doxycycline for the DOX-h-LA
group was 199.48%. Bioavailabilities as high as the one
reported in this manuscript for Dox-h-LA are not un-
common for formulations with prolonged absorption,
exhibiting flip-flop kinetics [17]. It has been proposed
that this phenomenon is either a fact or a flaw in
Table 1 Pharmacokinetic variables calculated for doxycycline (10 mg/kg) in dogs through compartmental analysis,
after either the IV, PO and SC administration of an aqueous solution, a preparation as tablet or the experimental long
acting preparation, respectively
Doxycycline IV Doxycycline PO Doxycycline SC
Mean ± SE Mean ± SE Mean ± SE
AUC0-∞ (μgh/mL) 97.34 ± 7.45a 72.89 ± 6.3b 194.18 ± 12.72c
AUCt (μgh/mL) 109.66 ± 8.56a 70.33 ± 6.23b 129.70 ± 9.56c
AUMCt (μgh2/mL) 909.64 ±23.82a 820.11 ± 18.63b 10453.52 ± 135.78c
RT (h) 10.10 ± 1.12a 10.22 ± 2.21a 166.63 ± 5.58b
K½ab (h) - 1.49 ± 0.07
-
K½el (h
-1) 2.87 ± 0.02a 5.59 ± 0.03b 45.21 ± 0.74c
A (h-1) 14.99 ± 0.11a - 2.16 ± 0.03b
B (h-1) 8.50 ± 0.07a - 0.86 ± 0.01b
α (h-1) 2.49 ± 0.02a - 0.07 ± 0.004b
β (h-1) 0.09 ± 0.003a - 0.005 ± 0.001
T½α (h-1) 0.28 ± 0.01 - 9.30 ± 0.36 b
T½β (h-1) 7.44 ± 0.06 a - 133.61 ± 6.32 b
Vdc (L/kg) 6.37 ± 0.76 -
-
Vdarea (L/kg) 1.49 ± 0.27 -
-
Vdss (L/kg) 11.34 ± 1.24 -
-
Cs0 (μg/mL) 23.54 ± 4.32 - -
Cmax (μg/mL) - 5.58 ± 0.5a 2.8 ± 0.3b
Tmax (h) - 3.88 ± 0.4
a 2.11 ± 0.12b
ClB (mL/kg  h-1) 134 ± 8 - -
F (%)* - 74.88 199.48
a,b,c,dThe values within a row with no common superscript differ significantly (P < 0.05).
AUC0-∞ = area under the concentration-time curve from zero up to ∞ with extrapolation of the terminal phase; AUMC = area under the first moment of the
concentration-time curve; AUCt = area under the concentration-time curve calculated by the trapezoidal method; AUMCt = area under the first moment of the
concentration-time curve calculated by the trapezoidal method; RT = retention time; K½el = elimination half rate constant from the central compartment; K½ab =
absorption half rate constant from the central compartment; A, B, = zero time intercepts of the distribution and post-distribution phases; α and β = hybrid rate
constants for the distribution and elimination phases, respectively; T½β = half-life of the elimination; Vdc= volume of the central compartment; Vdarea= Volume
calculated by the area method; Vdss = apparent volume of distribution at steady-state; Cs0 = calculated maximum plasma concentration at zero time; Cmax =
calculated maximum plasma concentration; Tmax = time of maximum plasma concentration; ClB = clearance from the body; F = bioavailability.
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misconceptions, analytical deficiencies or miscalculations
[15]. For example, it can be that depletion of doxycycline
after 24 h is based on fewer data points and bioavailabil-
ity is artificially overestimated. Yet, a careful review of
these and other factors listed by Toutain and Bousquet-
Mélou [15] offered no clear explanation as to the large
value of F obtained by the DOX-h-LA preparation injected
SC in this study, excepting, a recycling phenomenon due to
the noticeably high lipid solubility of this drug [25,26], and
its controlled release from the experimental preparation.
A flip – flop pharmacokinetic model can be estab-
lished by the overall appearance of the serum concentra-
tion vs. time profile of the drug, considering that the
rate of absorption is slower than the rate of elimination;
this is not always a clear-cut panorama. According to
[27] a flip-flop model can be recognized when the
plasma concentration-time profile tends either to closelyparallel rate of absorption. This provides a simple and
effective way to visualize the shape of the rate of absorp-
tion profile. Thus applying the following equation, a
"flip-flop" condition may be demonstrated for this
preparation:
Rate of Absorption ¼ VzðKCþ ðΔC=ΔtÞÞ
Where, Vz is the terminal exponential volume of distri-
bution, K is the terminal disposition rate constant once
drug absorption is complete (best determined from i.v.
dosing), C is the plasma concentration at time t and ΔC is
the change in plasma concentration over the time interval
Δt. For DOX-h-LA plasma concentration-time data at 48
and 72 hours, ΔC/Δt = 0.033 μg/mL/hour. At the midpoint
of this time period (60 h), (K)(C) = 2.1 μg/mL/hr. Since KC
>ΔC/Δt, rate of absorption rate of elimination, a "flip-
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can be regarded as a true long-acting one.
The poly(ethylene oxide)–poly(propylene oxide)–poly
(ethylene oxide) block copolymer (poloxamer) was used
as delivery vehicle-matrix, because it improves solubility,
reduces hydrolytic degradation, achieves controlled release
and often results in improved bioavailability [28,29]. In
part these effects are obtained by its reversed temperature-
dependant gelation. That is, the poloxamer-based formula-
tion exhibits low viscosity at room temperature and
becomes gel at body temperature [Rehman et al.]. It is
here postulated that DOX-h/β-cyclodextrin complexes
may diminish or prevent tissue irritation by reducing the
local concentration of free drug below the irritancy thresh-
old [[30]; 30], while enhancing absorption rate with a
priming phase [30,31]. The benefits of controlled delivery
of drugs include: the maintenance of serum drug concen-
tration at an optimal therapeutic level for a prolonged
time-interval, reduction in handling and consequently, a
possible improvement in drug-administration compliance
[32]. In this context, the DOX-h-LA preparation here
described was capable of providing, with a single SC injec-
tion, useful serum concentrations of this antibacterial drug
for 5 to 7 days, and no side effects were observed. Never-
theless, a complete toxicological analysis is necessary if this
drug preparation is to be used in dogs. Perhaps a key issue
to study further would be local tissue reactions that may
occur in skin sensitive dogs after repeated administrations
of this experimental preparation.
Although, it has been stated that high concentrations
of doxycycline in vitro, equivalent to 8 to 16 times the
value of an average MIC, could turn doxycycline into a
concentration-dependant antibacterial [33] cardiac tox-
icity of this drug has been reported in calves with a single
overdose 5-10 times larger with plasma concentrations ran-
ging from 50 - 100 μg/ml. Hence, seeking large Cmax
values appears to be an unsafe approach [34,35] and DOX
should be considered a time-dependant antibacterial drug
[33]. In that context PK/PD compliance can be achieved
when serum concentrations of the drug are barely above or
at the minimal inhibitory concentration (MIC) level of the
involved pathogen, but for as long as possible within the
dosing interval [36]. Values of MIC that can be adopted in
this trial can be set from 0.5 to 1.5 μg/mL [36]. Hence, the
length of time in which minimum therapeutic concentra-
tions can be achieved with DOX-h-PO varies from 12 to
24 h, and for DOX-h-LA this interval is extended to at least
7 days. Also, a PK/PD index accepted as predictor of thera-
peutic efficacy for tetracyclines as a group in humans is the
ratio of AUC at steady state (AUCss)/MIC [37]. AUCss was
not evaluated in this study. However if a pathogen is sus-
ceptible at 1.5 μg/mL, AUC DOX-h-LA/MIC ratio is 86.04
for DOX-h-LA, and only 46.72 for AUCDOX-h-PO/MIC.
Considering the above and the fact that serumconcentrations of doxycycline are ideally compelled to be
never below the MIC at any time during the dosing interval
[38], it is safe to regard DOX-h-LA as a drug preparation
that possesses better PK/PD ratios to control bacterial dis-
eases in dogs as compared to tablets or an IV solution. In
these latter cases serum concentrations of the drug will
show daily peaks and troughs as opposed to a more steady
serum concentrations achieved with DOX-h-LA.
Summarizing, DOX-h-LA is a preparation that opti-
mizes the use of doxycycline in dogs in terms of PK/
PD ratio congruency, and it is likely that it may also
improve prescription compliance. Nevertheless, clin-
ical trials and toxicological studies are needed to as-
sess if this preparation can be regarded as potentially useful
in this species.
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